$CRIS

CURIS INC (CRIS): Submission of Matters to a Vote of Security Holders

CURIS INC (CRIS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cris-20260625 0001108205 false 0001108205 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date

Original reporting
Published Jun 25, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 25, 2026, 8:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CRIS
Neutral
medium confidence
Mentioned
$CRIS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CRISNeutralLow
01

Why it matters

Because Proposal 1 passed, Curis has shareholder authorization to implement a reverse split within a broad 1-for-5 to 1-for-25 range, which can affect per-share price, liquidity, and investor perception.

02

Market read

This is a concrete corporate-action authorization event (reverse split) with immediate sentiment implications, but no execution details in the filing.

03

What to watch

Traders should watch for the board’s eventual chosen reverse-split ratio and any related financing/compliance disclosures, which are not included here.

Relevance 6/10Novelty 5/10Timing: after-hours/filing today following the June 25 special meeting vote

Background

The company held a special stockholder meeting to vote on charter amendments tied to a potential reverse stock split and an adjournment contingency.

Company-level read

Ticker impact

$CRISNeutralMedium confidence
Context

Curis reported special-meeting voting results approving a reverse stock split amendment (1-for-5 to 1-for-25) and an adjournment proposal.

Expected impact

Likely modest, two-sided reaction: reduced dilution/RSK stigma may help compliance optics, but reverse splits can pressure sentiment.

Evidence & confidence

The filing discloses the vote outcome and the reverse-split range, but provides no immediate execution date, ratio selection, or financial guidance.

Market effects

Limited read-across; reverse-split mechanics are company-specific and typically reflect listing/financing optics rather than sector fundamentals.

None material beyond US small-cap sentiment.

None.

Counterpoint

Approval alone may not change fundamentals until the board selects an exact ratio and implements the split; near-term trading could fade quickly.

Key entities

  • Curis, Inc.

    Nasdaq-listed issuer that submitted the 8-K reporting special-meeting voting results.

  • Proposal 1

    Amendments to the Restated Certificate of Incorporation to effect a reverse stock split at a board-determined ratio between 1-for-5 and 1-for-25.

  • Proposal 2

    Adjournment proposal to solicit additional proxies if Proposal 1 lacked sufficient votes.

Related articles

$CRISMedAI 8/10

Curis Prices $5.6 Million Offering Of Shares And Warrants; Stock Up

Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).

$CRISMed

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.

$CRISMedAI 8/10

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Curis (NASDAQ:C

Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.

$CRISMedAI 8/10

Curis stock jumps 11% on positive emavusertib trial data By Investing.com

Curis, Inc. (NASDAQ:CRIS) shares rose about 11% after the company reported updated emavusertib clinical data in primary CNS lymphoma and raised enrollment guidance for its chronic lymphocytic leukemia study. In PCNSL, it cited an 86% overall response rate in BTK inhibitor-naïve and 26% in BTKi-experienced patients as of July 1, 2026. For CLL, it guided year-end enrollment to 5-10 patients.

Big AI ambitions, cautious lenders: Naver’s $10b financing test

Naver and Brookfield are negotiating up to $9 billion in financing for the first phase of Naver's Gak Sejong AI data center expansion, which aims to increase capacity to 200 MW. The project requires significant investment in GPUs, complicating lenders' assessments of its commercial viability. Nvidia plans to invest $1 billion, and several Korean banks and securities firms are considering participation. The project's success could set a precedent for future AI infrastructure financing.

$WOLFHighAI 8/10

Wolfspeed Secures $1.5 Billion Financing from U.S. Department of Defense; Shares Surge Over 20% in After-Hours Trading

Wolfspeed (WOLF) received a $1.5B conditional financing commitment from the U.S. Department of Defense for a 30-year term to boost domestic production of silicon carbide and gallium nitride technologies. Shares surged 24% in after-hours trading. The deal includes warrants allowing the DoD to acquire up to 7.5% equity. Finalization is subject to due diligence and approvals.